Drug
Jzp926
Jzp926: highest development phase Phase 2/3, developed by Jazz Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| JZP926 capsule NCT07723963 | Phase 2/3 | Juvenile Myoclonic Epilepsy |
Latest
No recent events.
Follow Jzp926 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.